The Warburg effect: insights from the past decade.

Several decades ago, Otto Warburg discovered that cancer cells produce energy predominantly by glycolysis; a phenomenon now termed "Warburg effect". Warburg linked mitochondrial respiratory defects in cancer cells to aerobic glycolysis; this theory of his gradually lost its importance with the lack of conclusive evidence confirming the presence of mitochondrial defects in cancer cells. Scientists began to believe that this altered mechanism of energy production in cancer cells was more of an effect than the cause. More than 50 years later, the clinical use of FDG-PET imaging in the diagnosis and monitoring of cancers rekindled the interest of the scientific community in Warburg's hypothesis. In the last ten years considerable progress in the field has advanced our understanding of the Warburg effect. However, it still remains unclear if the Warburg effect plays a causal role in cancers or it is an epiphenomenon in tumorigenesis. In this review we aim to discuss the molecular mechanisms associated with the Warburg effect with emphasis on recent advances in the field including the role of epigenetic changes, miRNAs and post-translational modification of proteins. In addition, we also discuss emerging therapeutic strategies that target the dependence of cancer cells on altered energy processing through aerobic glycolysis.

[1]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[2]  A. P. Vo Glucose Metabolism in Cancer-Associated Fibroblasts , 2013 .

[3]  A. Guha,et al.  Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme , 2011, Neurobiology of Disease.

[4]  David A. Simpson,et al.  MicroRNA-155 Promotes Resolution of Hypoxia-Inducible Factor 1α Activity during Prolonged Hypoxia , 2011, Molecular and Cellular Biology.

[5]  Kishore Guda,et al.  The noncoding RNA, miR‐126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3‐kinase signaling and is frequently lost in colon cancers , 2008, Genes, chromosomes & cancer.

[6]  D. Martin,et al.  Clinical experience with 6-aminonicotinamide. , 1961, Cancer research.

[7]  F. Wang,et al.  Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. , 2011, Cancer research.

[8]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[9]  T. Suzuki,et al.  Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. , 1999, European journal of biochemistry.

[10]  R. Bucala,et al.  Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer , 2005, Clinical Cancer Research.

[11]  W. Sadee,et al.  Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia , 2007, Cancer Chemotherapy and Pharmacology.

[12]  K. O'Byrne,et al.  Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer , 2011, Cancers.

[13]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[14]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[15]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[16]  Jinke Cheng,et al.  SUMO-Specific Protease 1 Is Essential for Stabilization of HIF1α during Hypoxia , 2007, Cell.

[17]  P. Pandolfi,et al.  SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. , 2011, Cancer cell.

[18]  P. Pedersen,et al.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.

[19]  F. Sotgia,et al.  Using the “reverse Warburg effect” to identify high-risk breast cancer patients , 2012, Cell cycle.

[20]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[21]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[22]  Martin M Matzuk,et al.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. , 2010, Molecular endocrinology.

[23]  B. Ebert,et al.  Hypoxic Regulation of Lactate Dehydrogenase A , 1995, The Journal of Biological Chemistry.

[24]  P Vaupel,et al.  Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.

[25]  S. Arbuck,et al.  Clinical status and optimal use of topotecan. , 1997, Oncology.

[26]  T. Song,et al.  MiR-138 suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[27]  Michael C. Ostrowski,et al.  MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. , 2010, Molecular cell.

[28]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[29]  K P Fung,et al.  Increases in mRNA levels of glucose transporters types 1 and 3 in Ehrlich ascites tumor cells during tumor development , 1997, Journal of cellular biochemistry.

[30]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[31]  L. Bertrand,et al.  The Stimulation of Glycolysis by Hypoxia in Activated Monocytes Is Mediated by AMP-activated Protein Kinase and Inducible 6-Phosphofructo-2-kinase* , 2002, The Journal of Biological Chemistry.

[32]  Jun S. Song,et al.  Negative regulation of tumor suppressor p53 by microRNA miR-504. , 2010, Molecular cell.

[33]  James L. Park,et al.  A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. , 2008, American journal of physiology. Cell physiology.

[34]  B. Kefas,et al.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. , 2010, Neuro-oncology.

[35]  W. Linehan,et al.  The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine , 2004, Clinical Cancer Research.

[36]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[37]  H. Ji,et al.  MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene* , 2012, The Journal of Biological Chemistry.

[38]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[39]  C. Thompson,et al.  HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. , 2007, Cancer cell.

[40]  Jaime Caro,et al.  Hypoxia, glucose metabolism and the Warburg’s effect , 2007, Journal of bioenergetics and biomembranes.

[41]  Rhian M. Touyz,et al.  NADPH Oxidases, Reactive Oxygen Species, and Hypertension , 2008, Diabetes Care.

[42]  Wei Chen,et al.  Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. , 2011, Cancer research.

[43]  D. Stokoe,et al.  Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival , 2000, Current Biology.

[44]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[45]  Chi V. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[46]  F. Khuri,et al.  Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. , 2011, Molecular cell.

[47]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[48]  Joseph Loscalzo,et al.  MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. , 2009, Cell metabolism.

[49]  Jinke Cheng,et al.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. , 2007, Cell.

[50]  M. Minden,et al.  A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death , 2008, Molecular Cancer Therapeutics.

[51]  B. Dwarakanath,et al.  Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells , 2005, International journal of radiation biology.

[52]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[53]  F. Ismail-Beigi,et al.  Control of Glut1 promoter activity under basal conditions and in response to hyperosmolarity: role of Sp1. , 2006, American journal of physiology. Cell physiology.

[54]  H. Taegtmeyer,et al.  Compartmentation of hexokinase in rat heart. A critical factor for tracer kinetic analysis of myocardial glucose metabolism. , 1992, The Journal of clinical investigation.

[55]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[56]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[57]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[58]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[59]  P. Dobrzyn,et al.  Modification of thiamine pyrophosphate dependent enzyme activity by oxythiamine in Saccharomyces cerevisiae cells. , 2005, Canadian journal of microbiology.

[60]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. , 2005, Cold Spring Harbor symposia on quantitative biology.

[61]  Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme , 2011 .

[62]  Huamin Wang,et al.  Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy , 2012, PLoS biology.

[63]  I. Harris,et al.  Cancer cell metabolism. , 2011, Cold Spring Harbor symposia on quantitative biology.

[64]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[65]  A. Eberle,et al.  TT232, A Novel Signal Transduction Inhibitory Compound in the Therapy of Cancer and Inflammatory Diseases , 2005, Journal of receptor and signal transduction research.

[66]  H. Lodish,et al.  MicroRNA-125b is a novel negative regulator of p53. , 2009, Genes & development.

[67]  Gooitzen M van Dam,et al.  Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. , 2009, Medical hypotheses.

[68]  J. F. Hogg,et al.  Inhibition of anaerobic glycolysis in Ehrlich ascites tumor cells by 2-deoxy-D-glucose. , 1958, Cancer research.

[69]  Marta Martínez,et al.  Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. , 2004, The Biochemical journal.

[70]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[71]  M. Andreeff,et al.  Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. , 2009, Cancer research.

[72]  D. Vertommen,et al.  Phosphorylation and Activation of Heart 6-Phosphofructo-2-kinase by Protein Kinase B and Other Protein Kinases of the Insulin Signaling Cascades* , 1997, The Journal of Biological Chemistry.

[73]  Chi V Dang,et al.  Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? , 2010, Cell cycle.

[74]  M. You,et al.  Aerosolized 3-Bromopyruvate Inhibits Lung Tumorigenesis without Causing Liver Toxicity , 2012, Cancer Prevention Research.

[75]  J. Tuszynski,et al.  Cancer proliferation and therapy: the Warburg effect and quantum metabolism , 2010, Theoretical Biology and Medical Modelling.

[76]  M. Legiša,et al.  Posttranslational Modification of 6-phosphofructo-1-kinase as an Important Feature of Cancer Metabolism , 2011, PloS one.

[77]  Matthew K. Knabel,et al.  Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1 , 2011, Cell.

[78]  S. Arii,et al.  Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. , 2004, Journal of hepatology.

[79]  F. Welch,et al.  Causes and Consequences , 2017, Nature.

[80]  L. Neckers,et al.  Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway* , 2002, The Journal of Biological Chemistry.

[81]  S. Cook,et al.  MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. , 2010, Cardiovascular research.

[82]  Ken Garber,et al.  Energy Deregulation: Licensing Tumors to Grow , 2006, Science.

[83]  I. Tannock,et al.  Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. , 1986, Cancer research.

[84]  A. Lange,et al.  Fructose‐2,6‐bisphosphate and control of carbohydrate metabolism in eukaryotes , 1999, BioFactors.

[85]  D. Jump,et al.  Regulation of Rat Hepatic L-Pyruvate Kinase Promoter Composition and Activity by Glucose, n-3 Polyunsaturated Fatty Acids, and Peroxisome Proliferator-activated Receptor-α Agonist* , 2006, Journal of Biological Chemistry.

[86]  Shu Liu,et al.  Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. , 2010, Genes & development.

[87]  E. Yeh,et al.  SUMOylation and De-SUMOylation: Wrestling with Life's Processes* , 2009, Journal of Biological Chemistry.

[88]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.

[89]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[90]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[91]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[92]  S. Miyamoto,et al.  Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II , 2008, Cell Death and Differentiation.

[93]  A. Krogh,et al.  MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells , 2012, BMC Cancer.

[94]  T. Kwok,et al.  The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. , 2009, Carcinogenesis.

[95]  M. Andreeff,et al.  The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. , 2008, Cancer research.

[96]  O. Warburg On the origin of cancer cells. , 1956, Science.

[97]  K. Yanagisawa,et al.  Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. , 2008, Cancer research.

[98]  D. Mukhopadhyay,et al.  Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. , 2009, Blood.

[99]  Laurent Schwartz,et al.  Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. , 2006, Anticancer research.

[100]  M. Henry,et al.  MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. , 2009, European journal of cancer.

[101]  M. Seiki,et al.  Targeting the Warburg Effect That Arises in Tumor Cells Expressing Membrane Type-1 Matrix Metalloproteinase* , 2011, The Journal of Biological Chemistry.

[102]  A. Menssen,et al.  The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop , 2011, Proceedings of the National Academy of Sciences.

[103]  M. Gait,et al.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. , 2007, RNA.

[104]  M. Guéron,et al.  The inhibition of bovine heart hexokinase by 2-deoxy-D-glucose-6-phosphate: characterization by 31P NMR and metabolic implications. , 1992, Biochimie.

[105]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[106]  J. Rathmell,et al.  New roles for pyruvate kinase M2: working out the Warburg effect. , 2008, Trends in biochemical sciences.

[107]  F. Khuri,et al.  Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD+ Redox Homeostasis in Cancer Cells , 2011, Molecular and Cellular Biology.

[108]  A. Levine,et al.  Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect , 2011, Proceedings of the National Academy of Sciences.

[109]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[110]  D. Sabatini,et al.  Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. , 2010, Molecular cell.

[111]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[112]  J. Simons,et al.  2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. , 2003, Cancer cell.

[113]  Sandy D. Westerheide,et al.  The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression , 2001, Molecular and Cellular Biology.

[114]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[115]  T. Wong,et al.  Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling , 2008, International journal of cancer.

[116]  A. Levine,et al.  miR-143 regulates hexokinase 2 expression in cancer cells , 2013, Oncogene.

[117]  Geoffrey M. Cooper,et al.  The Cell A Molecular Approach Sixth Edition , 2013 .

[118]  David M. Sabatini,et al.  An Emerging Role of mTOR in Lipid Biosynthesis , 2009, Current Biology.

[119]  Zhengyu Zha,et al.  Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. , 2011, Molecular cell.

[120]  L. Huang,et al.  HIF‐1α induces cell cycle arrest by functionally counteracting Myc , 2004 .

[121]  P. Singh,et al.  Regulation of Aerobic Glycolysis by microRNAs in Cancer. , 2011, Molecular and cellular pharmacology.

[122]  R. Mccomb,et al.  Properties of particulate hexokinase of the Krebs-2 ascites tumor☆ , 1959 .

[123]  G. Daley,et al.  Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation , 2005, Oncogene.

[124]  Kwok-Kin Wong,et al.  Targeting the PI3K signaling pathway in cancer. , 2010, Current opinion in genetics & development.

[125]  B. Alberts,et al.  Molecular Biology of the Cell (Fifth Edition) , 2008 .

[126]  A. Ortega,et al.  A message emerging from development: the repression of mitochondrial β-F1-ATPase expression in cancer , 2007, Journal of bioenergetics and biomembranes.

[127]  Jing Wang,et al.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.

[128]  P. Ratcliffe,et al.  Regulation of HIF by the von Hippel‐Lindau Tumour Suppressor: Implications for Cellular Oxygen Sensing , 2001, IUBMB life.

[129]  W. Mcguire CLINICAL STATUS AND OPTIMAL USE OF TOPOTECAN , 1997 .

[130]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.

[131]  Yu Hu,et al.  miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. , 2012, Oncology reports.

[132]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[133]  Alice Shapiro,et al.  MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.

[134]  C. Sapienza,et al.  Epigenetic Differences in Normal Colon Mucosa of Cancer Patients Suggest Altered Dietary Metabolic Pathways , 2012, Cancer Prevention Research.

[135]  S. Vatner,et al.  Downregulation of MiR-199a Derepresses Hypoxia-Inducible Factor-1α and Sirtuin 1 and Recapitulates Hypoxia Preconditioning in Cardiac Myocytes , 2009, Circulation research.

[136]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[137]  R L Wahl,et al.  An Immunohistochemical Study , 2006 .

[138]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[139]  Peng Huang,et al.  The Warburg effect and its cancer therapeutic implications , 2007, Journal of bioenergetics and biomembranes.

[140]  G. Rutter,et al.  miR-29a and miR-29b Contribute to Pancreatic β-Cell-Specific Silencing of Monocarboxylate Transporter 1 (Mct1) , 2011, Molecular and Cellular Biology.

[141]  Sung Hyun Kim,et al.  Down-regulation of lactate dehydrogenase-A by siRNAs for reduced lactic acid formation of Chinese hamster ovary cells producing thrombopoietin , 2007, Applied Microbiology and Biotechnology.

[142]  Yong Li,et al.  A novel miR‐155/miR‐143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells , 2012, The EMBO journal.

[143]  G. Semenza,et al.  HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[144]  D. Hardie The AMP-activated protein kinase pathway – new players upstream and downstream , 2004, Journal of Cell Science.

[145]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[146]  A. Levine,et al.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.

[147]  R. Cole,et al.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. , 2009, Anticancer research.

[148]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[149]  H. Lee,et al.  Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. , 2007, Anticancer research.

[150]  P. Pedersen,et al.  Glucose Metabolism in Cancer , 2003, The Journal of Biological Chemistry.

[151]  Donna D. Zhang,et al.  Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. , 2009, Molecular cell.

[152]  P. Ditonno,et al.  Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. , 2005, Reviews in urology.

[153]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[154]  Sean Davis,et al.  Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis , 2009, Molecular Cancer Research.

[155]  Robert J. Gillies,et al.  Causes and Consequences of Increased Glucose Metabolism of Cancers , 2008, Journal of Nuclear Medicine.

[156]  P. Bottoni,et al.  Glycolytic enzyme inhibitors in cancer treatment. , 2008, Expert opinion on investigational drugs.

[157]  A. Vaquero,et al.  The dual role of sirtuins in cancer. , 2011, Genes & cancer.

[158]  F. Domann,et al.  Metabolic defects provide a spark for the epigenetic switch in cancer. , 2009, Free radical biology & medicine.

[159]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[160]  R A Brooks,et al.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography , 1982, Neurology.

[161]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[162]  Zhaohui Lu,et al.  The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. , 2010, Carcinogenesis.

[163]  Wenzhe Ma,et al.  A pivotal role for p53: balancing aerobic respiration and glycolysis , 2007, Journal of bioenergetics and biomembranes.

[164]  J. Bertoni,et al.  Competitive Inhibition of Rat Brain Hexokinase by 2‐Deoxyglucose, Glucosamine, and Metrizamide , 1981, Journal of neurochemistry.

[165]  J. Barrett,et al.  HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. , 2004, The EMBO journal.

[166]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[167]  S. Lowe,et al.  miR-19 is a key oncogenic component of mir-17-92. , 2009, Genes & development.

[168]  R. Strausberg,et al.  Transcriptional response to hypoxia in human tumors. , 2001, Journal of the National Cancer Institute.

[169]  Sabita Roy,et al.  Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. , 2010, The Journal of clinical investigation.

[170]  Jun Yu,et al.  Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis , 2010, Oncogene.

[171]  X. Chen,et al.  Role of miR-143 targeting KRAS in colorectal tumorigenesis , 2009, Oncogene.

[172]  D. Colomer,et al.  Control of phosphofructokinase by fructose 2,6-bisphosphate in B-lymphocytes and B-chronic lymphocytic leukemia cells. , 1987, Cancer research.

[173]  E. Newsholme,et al.  High Km glucose-phosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose. , 1995, Cancer research.

[174]  N. Savaraj,et al.  Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression , 2005, Pancreas.

[175]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[176]  B. Silvestrini,et al.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.

[177]  A. Mangoni,et al.  Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions , 2008, Journal of experimental & clinical cancer research : CR.

[178]  N. Baroukh,et al.  miR-375 Targets 3′-Phosphoinositide–Dependent Protein Kinase-1 and Regulates Glucose-Induced Biological Responses in Pancreatic β-Cells , 2008, Diabetes.

[179]  K. Kumamoto,et al.  Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[180]  Chuong D. Hoang,et al.  Oxidative stress‐responsive microRNA‐320 regulates glycolysis in diverse biological systems , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[181]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[182]  B. Zhivotovsky,et al.  Mitochondria in cancer cells: what is so special about them? , 2008, Trends in cell biology.

[183]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[184]  Robert J Gillies,et al.  Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. , 2003, Neoplasia.

[185]  G. Semenza HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[186]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[187]  L. Neckers,et al.  Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. , 2002, The Journal of biological chemistry.

[188]  E. Kandel,et al.  Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. , 2001, Genes & development.

[189]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[190]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[191]  P. Puigserver,et al.  A Hypoxia-Induced Positive Feedback Loop Promotes Hypoxia-Inducible Factor 1α Stability through miR-210 Suppression of Glycerol-3-Phosphate Dehydrogenase 1-Like , 2011, Molecular and Cellular Biology.

[192]  P. Jaakkola,et al.  Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. , 2004, The Biochemical journal.

[193]  J. Roh,et al.  MicroRNAs Induced During Ischemic Preconditioning , 2010, Stroke.

[194]  J. Chang,et al.  Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model. , 2007, Academic radiology.

[195]  P. Pedersen,et al.  Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. , 1988, Cancer research.

[196]  K. Thangaraj,et al.  Cellular Model of Warburg Effect Identifies Tumor Promoting Function of UCP2 in Breast Cancer and Its Suppression by Genipin , 2011, PloS one.

[197]  Saroj P. Mathupala,et al.  Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target , 2010, Cancer biology & therapy.

[198]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[199]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[200]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[201]  D. Jayne,et al.  Targeting Glucose Metabolism: An Emerging Concept for Anticancer Therapy , 2011, American journal of clinical oncology.

[202]  Yong Li,et al.  Negative Regulation of the Tumor Suppressor p53 Gene by MicroRNAs , 2010, Oncogene.

[203]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[204]  Borivoj Vojnovic,et al.  MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU , 2010, PloS one.

[205]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[206]  M. Cascante,et al.  Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle , 1999, FEBS letters.

[207]  J. Joseph,et al.  Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. , 2012, Cancer research.

[208]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. , 2004, Molecular cancer therapeutics.

[209]  Takeshi Kimura,et al.  MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. , 2009, Biochemical and biophysical research communications.

[210]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[211]  Ning Li,et al.  Promoter Hypermethylation Mediated Downregulation of FBP1 in Human Hepatocellular Carcinoma and Colon Cancer , 2011, PloS one.

[212]  I. Nabi,et al.  Regulation of the formation of tumor cell pseudopodia by the Na(+)/H(+) exchanger NHE1. , 2000, Journal of cell science.

[213]  G. Cooper The Cell: A Molecular Approach , 1996 .

[214]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[215]  Ming-Rong Wang,et al.  Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth , 2011, Proceedings of the National Academy of Sciences.

[216]  Divya Pathania,et al.  Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. , 2009, Advanced drug delivery reviews.

[217]  Peng Huang,et al.  Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism , 2006, The Journal of cell biology.

[218]  R. Kannagi Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression—The Warburg effect revisited , 2003, Glycoconjugate Journal.

[219]  H. Barrach,et al.  Inhibition of NADP dependent oxidoreductases by the 6‐aminonicotinamide analogue of NADP , 1970, FEBS letters.

[220]  A. Halestrap,et al.  The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia through a HIF-1α-dependent Mechanism* , 2006, Journal of Biological Chemistry.

[221]  C. V. van Veelen,et al.  Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas. , 1987, Cancer research.

[222]  P. Ratcliffe,et al.  Hypoxia and the regulation of gene expression. , 1998, Molecular medicine today.